2.
热消融治疗NSCLC的临床研究
Clinical study of thermal ablation for NSCLC
| Study title | Interventions | Phase | Outcome measures | Number enrolled | Time limit | NCT number | |
| EGFR: epidermal growth factor receptor; RFA: radiofrequency ablation; DFS: disease free survival; PFS: progression free survival; ORR: objective response rate; OS: overall survival; AE: adverse event. | |||||||
| Mitochondria-targeted system therapy combined with radiofrequency ablation for early-stage NACLC | Mitochondria-targeted system therapy RFA | NA | DFS, OS | 1, 753 | 2019.01.31 2024.01.31 | NCT03840408 | |
| Evaluating the safety and efficacy of pembrolizumab combined with MWA for advanced NSCLC | Pembrolizumab MWA | NA | OS, AE, PFS | 100 | 2018.11.01 2020.11.01 | NCT03769129 | |
| Microwave plus chemotherapy versus chemotherapy for advanced NSCLC | MWA chemotherapy | Phase 3 | PFS | 275 | 2015.01 2018.05 | NCT02455843 | |
| Local ablative therapy for treatment of oligoprogressive, EGFR-mutated, non-small cell lung cancer after treatment with Osimertinib | Osimertinib local ablative | Phase 2 | PFS, ORR | 100 | 2016.04.13 2022.09.01 | NCT02759835 | |
| Microwave ablation in the treatment of stage Ⅰ NSCLC | MWA | Phase 3 | OS, DFS | 150 | 2016.09 2019.09 | NCT02896166 | |